Myleme Harrison, MD
Psychiatry · Raleigh, NCNPI 1164477691
Payments from drug & device makers
Across 866 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$919
- Neurocrine Biosciences, Inc.$916
- plus $4K from 20 others
What the payments were for
- Food & beverage$12,497100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 238 | $2,146 |
| Otsuka America Pharmaceutical, Inc. | 93 | $1,817 |
| Johnson & Johnson | 68 | $1,369 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 114 | $1,254 |
| Alkermes, Inc. | 46 | $919 |
| Neurocrine Biosciences, Inc. | 50 | $916 |
| Teva Pharmaceuticals USA, Inc. | 69 | $870 |
| Vanda Pharmaceuticals Inc. | 34 | $627 |
| Sunovion Pharmaceuticals Inc. | 48 | $573 |
| E.r. Squibb & Sons, L.L.C. | 19 | $409 |
| Indivior Inc. | 18 | $359 |
| Lundbeck LLC | 14 | $280 |
| Braeburn Inc. | 8 | $172 |
| Avanir Pharmaceuticals, Inc. | 10 | $158 |
| MDD US Operations, LLC | 7 | $121 |
| Almatica Pharma LLC | 6 | $101 |
| Corium, LLC | 4 | $89 |
| Ironshore Pharmaceuticals Inc. | 6 | $87 |
| Orexo US, Inc. | 3 | $44 |
| Noven Therapeutics, LLC | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$115
How this compares
$12,500 in reported general payments places this provider in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 40 | $358,347 |
| Invega SustennaPaliperidone Palmitate | 98 | $358,123 |
| VraylarCariprazine Hcl | 157 | $244,209 |
| Invega TrinzaPaliperidone Palmitate | 12 | $108,246 |
| CaplytaLumateperone Tosylate | 46 | $79,473 |
| RexultiBrexpiprazole | 38 | $62,623 |
| Abilify MaintenaAripiprazole | 12 | $37,233 |
| UzedyRisperidone | 11 | $24,261 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,127 |
| Lurasidone Hcl | 128 | $15,239 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 172 | $11,343 |
| BelsomraSuvorexant | 21 | $9,172 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 38 | $8,244 |
| Hydroxyzine Hcl | 198 | $3,626 |
| Atomoxetine Hcl | 31 | $3,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,369 | $466,368110 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $916 | $358,34740 claims |
| AbbVieVraylar | $2,146 | $244,209157 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,817 | $99,85550 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,254 | $79,47346 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $870 | $24,26111 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $158 | $18,12712 claims |
| Indivior Inc.Suboxone | $359 | $8,24438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Raleigh
- Richard WeislerRaleigh$1.2M
- Robert MilletRaleigh$517K
- Ashwin PatkarRaleigh$170K
- Mona GuptaRaleigh$88K
- Kellie TolinRaleigh$31K
- Celso LobaoRaleigh$28K
- Elizabeth CoxRaleigh$24K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.